| Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study NM Kuderer, TK Choueiri, DP Shah, Y Shyr, SM Rubinstein, DR Rivera, ... The Lancet 395 (10241), 1907-1918, 2020 | 1826 | 2020 |
| COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection H Al-Samkari, RS Karp Leaf, WH Dzik, JCT Carlson, AE Fogerty, ... Blood, The Journal of the American Society of Hematology 136 (4), 489-500, 2020 | 1359 | 2020 |
| Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice LV Sequist, RS Heist, AT Shaw, P Fidias, R Rosovsky, JS Temel, ... Annals of Oncology 22 (12), 2616-2624, 2011 | 470 | 2011 |
| Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium P Grivas, AR Khaki, TM Wise-Draper, B French, C Hennessy, CY Hsu, ... Annals of oncology 32 (6), 787-800, 2021 | 287 | 2021 |
| Diagnosis, treatment and follow up of acute pulmonary embolism: consensus practice from the PERT consortium B Rivera-Lebron, M McDaniel, K Ahrar, A Alrifai, DM Dudzinski, C Fanola, ... Clinical and Applied Thrombosis/Hemostasis 25, 1076029619853037, 2019 | 263 | 2019 |
| A multidisciplinary pulmonary embolism response team: initial 30-month experience with a novel approach to delivery of care to patients with submassive and massive pulmonary … C Kabrhel, R Rosovsky, R Channick, MR Jaff, I Weinberg, T Sundt, ... Chest 150 (2), 384-393, 2016 | 231 | 2016 |
| Long-term outcomes of the New Pathway Program at Harvard Medical School: a randomized controlled trial AS Peters, R Greenberger-Rosovsky, C Crowder, SD Block, GT Moore Academic Medicine 75 (5), 470-479, 2000 | 223 | 2000 |
| Prediction and prevention of thromboembolic events with enoxaparin in cancer patients with elevated tissue factor‐bearing microparticles: a randomized‐controlled phase II trial … JI Zwicker, HA Liebman, KA Bauer, T Caughey, F Campigotto, ... British journal of haematology 160 (4), 530-537, 2013 | 177 | 2013 |
| Association of convalescent plasma therapy with survival in patients with hematologic cancers and COVID-19 MA Thompson, JP Henderson, PK Shah, SM Rubinstein, MJ Joyner, ... JAMA oncology 7 (8), 1167-1175, 2021 | 169 | 2021 |
| Direct oral anticoagulants for the treatment of acute venous thromboembolism associated with cancer: a systematic review and meta-analysis M Giustozzi, G Agnelli, J del Toro-Cervera, FA Klok, RP Rosovsky, ... Thrombosis and haemostasis 120 (07), 1128-1136, 2020 | 130 | 2020 |
| Thrombosis, bleeding, and the observational effect of early therapeutic anticoagulation on survival in critically ill patients with COVID-19 H Al-Samkari, S Gupta, RK Leaf, W Wang, RP Rosovsky, SK Brenner, ... Annals of internal medicine 174 (5), 622-632, 2021 | 126 | 2021 |
| Changes in treatment and outcomes after creation of a pulmonary embolism response team (PERT), a 10-year analysis R Rosovsky, Y Chang, K Rosenfield, R Channick, MR Jaff, I Weinberg, ... Journal of thrombosis and thrombolysis 47, 31-40, 2019 | 121 | 2019 |
| Comparison of published guidelines for management of coagulopathy and thrombosis in critically ill patients with COVID 19: implications for clinical practice and future … A Flaczyk, RP Rosovsky, CT Reed, BK Bankhead-Kendall, EA Bittner, ... Critical Care 24, 1-13, 2020 | 106 | 2020 |
| Catheter-related thrombosis in cancer patients: pathophysiology, diagnosis, and management RP Rosovsky, DJ Kuter Hematology/Oncology Clinics 19 (1), 183-202, 2005 | 101 | 2005 |
| Contemporary management and outcomes of patients with massive and submassive pulmonary embolism E Secemsky, Y Chang, CC Jain, JA Beckman, J Giri, MR Jaff, ... The American journal of medicine 131 (12), 1506-1514. e0, 2018 | 97 | 2018 |
| SELECT: A multicenter phase II trial of adjuvant erlotinib in resected early-stage EGFR mutation-positive NSCLC. NA Pennell, JW Neal, JE Chaft, CG Azzoli, PA Janne, R Govindan, ... Journal of Clinical Oncology 32 (15_suppl), 7514-7514, 2014 | 89 | 2014 |
| NCCN guidelines insights: hematopoietic growth factors, version 1.2020: featured updates to the NCCN guidelines PS Becker, EA Griffiths, LM Alwan, K Bachiashvili, A Brown, R Cool, ... Journal of the National Comprehensive Cancer Network 18 (1), 12-22, 2020 | 86 | 2020 |
| What is the evidence for the off-label use of recombinant factor VIIa (rFVIIa) in the acute reversal of warfarin? RP Rosovsky, MA Crowther ASH Education Program Book 2008 (1), 36-38, 2008 | 86 | 2008 |
| Evaluation of andexanet alfa and four‐factor prothrombin complex concentrate (4F‐PCC) for reversal of rivaroxaban‐and apixaban‐associated intracranial hemorrhages ME Barra, AS Das, BD Hayes, ES Rosenthal, RP Rosovsky, L Fuh, ... Journal of Thrombosis and Haemostasis 18 (7), 1637-1647, 2020 | 81 | 2020 |
| Pulmonary embolism response teams: Purpose, evidence for efficacy, and future research directions R Rosovsky, K Zhao, A Sista, B Rivera‐Lebron, C Kabrhel Research and practice in thrombosis and haemostasis 3 (3), 315-330, 2019 | 80 | 2019 |
